Glaukos rolls on with direct sales conversion for new-gen iStent
This article was originally published in Clinica
Executive Summary
US ophthalmology firm Glaukos is expanding its global direct sales presence, eschewing the distributor approach, as it rolls out its new generation micro-stent device for glaucoma patients.
You may also be interested in...
Glaukos Submits PMA For iStent, Second-Generation MIGS Device For Treating Glaucoma
Glaukos Corp. announced on Dec. 27 it has submitted a pre-market approval application to US FDA for its second-generation minimally invasive glaucoma surgery (MIGS) iStent device used for treating glaucoma, the second-leading cause of blindness.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.